Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines

Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor

(2016) J. Van den Bossche et al.   MEDICINAL RESEARCH REVIEWS

BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments

(2015) Rodrigo F.E. Bogado et al.   ANTI-CANCER DRUGS

Prognostic significance of polo-like kinases in retinoblastoma: correlation with patient outcome, clinical and histopathological parameters

(2015) Lata Singh et al.   CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors

(2015) Melanie Schwermer et al.   Oncotarget

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies

(2014) C-C Lin et al.   BRITISH JOURNAL OF CANCER

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy

(2014) B T Gjertsen et al.   LEUKEMIA

Bora and Aurora-A continue to activate Plk1 in mitosis

(2013) Wytse Bruinsma et al.   JOURNAL OF CELL SCIENCE

Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program

(2013) Richard Gorlick et al.   PEDIATRIC BLOOD & CANCER

Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells

(2012) Peter S Harris et al.   BMC CANCER

Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications

(2012) Francis L Munier et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Retinoblastoma

(2012) Helen Dimaras et al.   LANCET

Analysis of MDM2 and MDM4 Single Nucleotide Polymorphisms, mRNA Splicing and Protein Expression in Retinoblastoma

(2012) Justina McEvoy et al.   PLoS One

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

(2011) D. Olmos et al.   CLINICAL CANCER RESEARCH

Polo-Like Kinase 1 is a Therapeutic Target in High-Risk Neuroblastoma

(2010) S. Ackermann et al.   CLINICAL CANCER RESEARCH

Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells

(2010) N N Kreis et al.   ONCOGENE

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

(2009) D. Rudolph et al.   CLINICAL CANCER RESEARCH

Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness

(2009) F Cimmino et al.   ONCOGENE

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology

(2009) P. Schoffski   ONCOLOGIST

The Cdc14B-Cdh1-Plk1 Axis Controls the G2 DNA-Damage-Response Checkpoint

(2008) Florian Bassermann et al.   CELL

Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression

(2008) Zheng Fu et al.   NATURE CELL BIOLOGY